Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Thoracic 7Head & Neck 5Breast 4Gynecologic 3Dermatologic 3Other solid neoplasm 2Genitourinary 2Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Temozolomide 19Bevacizumab 14Irinotecan 12Carboplatin 10Cyclophosphamide 9Radiosurgery 8Lomustine 8Radiotherapy 7pembrolizumab 6Vincristine 6Topotecan 6Drug Therapy 6Surgical Procedures, Operative 5Etoposide 5Doxorubicin 5Cisplatin 53-Iodobenzylguanidine 5trametinib 4Metformin 4Gemcitabine 4Dexamethasone 4Blood Specimen Collection 4poly ICLC 3dabrafenib 3Vorinostat 3Trastuzumab 3Therapeutics 3Radiation 3Paclitaxel 3Observation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × budigalimab × CNS × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡